IC 800 is a potent analgesic and anti-inflammatory compound

It harnesses the power of DENKI technology for post-surgical applications, like pain management after cataract surgery. Its sister compound, IC 805, will be used in chronic cases to alleviate neuropathic pain and pain associated with dry eye.

IC 800 offers a number of benefits:

New non-opioid pain management option in the making

Potential for an effective anti‑inflammatory effect

May be more effective than steroids and NSAIDs

Possible decline in abuse and safety concerns associated with opioid drugs

IACTA’s R&D in action

IC 800 uses our proprietary molecule DENKI to inhibit enzymes that degrade the body’s natural response to pain. DENKI can increase the local concentrations of enkephalins, the opioid peptides produced by the body to relieve pain.

Learn more about DENKI

IC 800: Development strategy

Scientific and clinical validation

  • Preclinical ocular studies in animals demonstrated that the drug was effective, safe, and well tolerated

Formulation

  • Complete development of ocular formulation

  • Open Investigational New Drug (IND) application with US FDA

Clinical Development

  • Open Investigational New Drug (IND) application with US FDA

  • Conduct Phase 1 study, then Phase 2 study, in dry eye patients

View other products

IC 805

for chronic pain relating to neuropathic pain and pain associated with dry eye

Learn more

IC 270

for allergic conjunctivitis

Learn more

IC 265

for the treatment of dry eye

Learn more